Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer ...Middle East

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™...

Read More Details
Finally We wish PressBee provided you with enough information of ( Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer )

Also on site :

• 'Days of Our Lives' Icon, 74, Makes Bold Confession About Character
• Country Artist Cancels Shows Following Tragic Accident
• Yingli Solar veröffentlicht ESG-Jahresbericht